| Zdroj: |
BASE-Bielefeld Academic Search Engine
Dejgaard, T F, Johansen, N B, Frandsen, C S, Asmar, A, Tarnow, L, Knop, F K, Madsbad, S & Andersen, H U 2017, ' Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes ', Diabetes, Obesity and Metabolism Online, vol. 19, no. 5, pp. 734-738 . https://doi.org/10.1111/dom.12841 |
| Popis: |
We investigated the short-term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m(2) ) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial. At baseline and after 24 weeks of treatment, 24-hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima-media thickness were evaluated. Compared with placebo, liraglutide increased 24-hour heart rate by 4.6 beats per minute (BPM); P = .0015, daytime heart rate by 3.7; P = .0240 and night-time heart rate by 7.5 BPM; P |
Plný text 